Clinical Trials Logo

B-cell Lymphoma Recurrent clinical trials

View clinical trials related to B-cell Lymphoma Recurrent.

Filter by:

NCT ID: NCT03853616 Recruiting - Clinical trials for B-cell Lymphoma Refractory

MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)

Start date: November 26, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase l/ll multi-centric, single arm, prospective open, dose-escalation study in patients with relapsed or refractory CD19-positive B cell malignancies (ALL, NHL, CLL). The trial will include adult and pediatric patients. The trial consists of 2 parts: Part I and Part II. In total approximately 48 patients will be included in Part I of the trial. There will be three individual cohorts, defined by disease biology: pediatric ALL and aggressive pediatric NHL (Cohort 1), adult ALL (Cohort 2) and adult NHL/CLL (Cohort 3).

NCT ID: NCT03757000 Recruiting - Clinical trials for B-cell Chronic Lymphocytic Leukemia

A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies

Start date: December 25, 2017
Phase: Phase 1
Study type: Interventional

Protocol YY-20394-001 is a phase I open-label, first in human, dose escalation study to assess the tolerability, pharmacokinetics (PK) and efficacy of YY-20394 in patients with relapse or refractory B cell malignant hematological tumor.

NCT ID: NCT03664635 Active, not recruiting - Clinical trials for Non-Hodgkin's Lymphoma

MB-CART20.1 Lymphoma

Start date: September 25, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This trial is a phase I/II trial to assess safety, dose finding and feasibility of ex vivo generated MB-CART20.1 cells in patients with relapsed or refractory CD20 positive B-NHL.

NCT ID: NCT02843061 Completed - Clinical trials for B-cell Lymphoma Recurrent

Combination of Rituximab and NK Immunotherapy for B Lymphoma

Start date: July 1, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this study is the safety and efficacy of Rituximab plus NK immunotherapy to recurrent B lymphoma.